SciClone Pharmaceuticals Inc. (NASDAQ:SCLN) of San Mateo,Calif. announced that it has restructured its Singapore jointventure to give SciClone 100 percent ownership and totaloperating control of the venture. SciClone's partners SingaporeBio-Innovations and Transpac Capital Pte. Ltd. have convertedtheir equity in the joint venture into 175,000 shares ofSciClone's restricted common stock.

(c) 1997 American Health Consultants. All rights reserved.

No Comments